Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Shining a light on an alternative treatment for MRSA

03.04.2006


Cosmetic considerations and a perceived lack of patent opportunities could be stopping the pharmaceutical and healthcare industries from investing in the development of a new therapy proven to be effective in the treatment of MRSA.



According to a leading scientist based at Liverpool John Moores University (LJMU) photodynamic or dye therapy could be an effective alternative therapy for the hospital superbug.

Around 5000 people die and many thousands more suffer long term complications in the UK every year as a result of infections caused by superbugs such as MRSA. These fatal bacterial infections are increasing because of drug resistance, most worryingly to vancomycin, the drug of last resort. Common disinfectant drugs, like mupirocin, are also becoming less and less effective.


Dr Mark Wainwright, a senior LJMU lecturer in medicinal chemistry, who has been researching the therapy for nearly 20 years, explained: “After decades of wonder drugs, man’s supremacy over the microbe is over. Over-prescription and misuse of antibacterial drugs are to blame for this rise in resistance and we urgently need to change the way in which we employ such valuable drugs.”

He continued: “Photodynamic therapy could be an effective alternative treatment. If antibiotics use a sniper’s approach to killing infections, dye therapy is like a hand grenade. Bacteria and viruses have no defence against the active oxygen it releases. The Darwinian argument of ‘survival of the fittest’ doesn’t apply because all of the bacterial cells are destroyed so they can’t develop resistance to the therapy. Its low human toxicity and the local/topical application of the drugs also mean that patients have fewer side effects.”

Photodynamic therapy (PDT) is a relatively straightforward and cheap therapy. It works by the topical application of light sensitive compounds (related to dyes) onto the infected area and then shining light onto it.

The light causes the dye to produce a highly reactive form of oxygen in situ, which if released close enough to a bacteria or virus, kills them, halting the infection.

The therapy doesn’t even require expensive lasers as the right wavelength can be provided by ordinary light sources.

At the moment, the therapy is limited to areas of the body accessible to light sources but this would still allow for the treatment of a wide range of bacterial diseases, skin infections, burns and wounds.

“An enormous amount of money is currently spent by the NHS every year on treating such conditions, many of which end up being colonised with MRSA,” said Dr Wainwright.

“These infections could be treated effectively using PDT out in the local community, helping prevent the introduction of potentially lethal infections into the hospital environment.”

Many of PDT’s light sensitive dyes – or photosensitisers – have been used clinically for a long time; many before the discovery of penicillin. One of the lead compounds, methylene blue, for example, was first used therapeutically in 1891 against malaria.

Photodynamic (dye) therapy has been successfully used to treat certain cancers for around 25 years, but so far the UK’s pharmaceutical and healthcare industries have been reluctant to investigate further uses.

Dr Wainwright believes that this is partly because photosensitisers are the poor relations in the pharmaceutical industry, often classified as textile dyes rather than drugs.

Potential profits are also limited because the dyes currently in use are already established, but novel compounds with new patent opportunities are available.

In addition, the effectiveness of photosensitisers as disinfectants has already been proved to great effect by the National Blood Service, who use photodisinfection to ensure the safety of blood plasma products.

Overseas, Russian scientists are using photosensitisers to treat multi-drug-resistant forms of TB, while dye therapy using another old dye, gentian violet, has been successful in the treatment of MRSA-infected patients in Japan.

So why hasn’t the UK’s pharmaceutical industry been more receptive?

Dr Wainwright believes cosmetic concerns may also be to blame. He explained: “There’s a general dislike of coloured staining medication and it’s true in the past patients were often heavily stained. But the stains are only temporary and as the number of life-threatening pathogens, such as MRSA, increases, surely this is a price worth paying if it saves lives?”

Dr Wainwright is now in pursuit of new funding to support clinical trials to test the efficacy of photobactericidal agents in the treatment of bacterial infections.

Shonagh Wilkie | alfa
Further information:
http://www.livjm.ac.uk

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>